Viatris Aims To Clear Up Investor ‘Disappointment’ After Breaking EBITDA Baseline
Company Also Reiterates $9bn Pre-Tax Proceeds Goal Via Divestments
Days after Viatris announced a landmark new direction – the divestment of its global biosimilars plus other assets – and its full-year 2021 earnings, company management spoke with a leading investment bank to clarify issues raised by Viatris’ shareholders.
